
Deals· August 5, 2026 · 19 min read
Lilly's $3.8B AtaiBeckley deal: big pharma validates psychedelics for TRD
By Ran Chen#M&A#Eli Lilly#Psychedelic Therapy
Psychedelic-assisted therapy clinical pipeline, 5-HT2A super-agonists, MDMA, psilocybin, and REMS monitoring infrastructure.

